Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Mounjaro in India rose 60% in May from April, the first full month the popular weight loss/diabetes drug was available in the ...

Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting ...

The manufacturer of Mounjaro has responded to dangerous hack that’s been doing the rounds on social media. Videos of people ...

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly’s revenue was further bolstered by Mounjaro, its blockbuster diabetes drug. Mounjaro’s sales soared to $2.21 billion for the quarter, a dramatic increase from $279.2 million in the ...